rifaximin (L 105)

04/01/2014 - "Over a 6-month period, treatment with Rifaximin failed to maintain remission from hepatic encephalopathy more effectively than placebo in the studied group."
03/25/2010 - "Over a 6-month period, treatment with rifaximin maintained remission from hepatic encephalopathy more effectively than did placebo. "
10/15/2007 - "In contrast, rifaximin is safe and effective in hepatic encephalopathy, but is more expensive. "
01/01/2013 - "Many studies have found that the antibiotic rifaximin is effective for the treatment of hepatic encephalopathy. "
05/01/2014 - "Rifaximin is widely used for the treatment of hepatic encephalopathy. "

08/01/2015 - "Clinically, rifaximin 600 mg/d significantly reduced symptoms of travelers' diarrhea (eg, time to last unformed stool vs placebo [32.0 hours vs 65.5 hours, respectively; P=.001]). "
05/17/2005 - "Rifaximin provided 72% and 77% protection against travelers' diarrhea and antibiotic-treated travelers' diarrhea, respectively (P < 0.001 for both), and all rifaximin doses were superior to placebo. "
10/01/2015 - "Rifaximin can be effective for chronic diarrhea associated with IBS and small intestinal bacterial overgrowth. "
09/01/2011 - "Rifaximin has been shown to be effective in treating and preventing travelers' diarrhea (TD) during the summer season. "
01/01/2011 - "Rifaximin Is Effective for the Treatment of Clostridium difficile-Associated Diarrhea: Results of an Open-Label Pilot Study."

07/01/2014 - "Clinical studies indicate that rifaximin is beneficial in treating irritable bowel syndrome (IBS). "
05/17/2005 - "Future studies should evaluate whether rifaximin is effective in preventing postinfectious irritable bowel syndrome."
06/01/2012 - "Sequential treatment with rifaximin/probiotics seems to be effective for symptom and fermentative profile improvement in irritable bowel syndrome patients."
03/01/2009 - "Therefore, rifaximin may be useful in the treatment of gastrointestinal disorders associated with altered bacterial flora, including irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO). "
09/01/2015 - "Multiple data were presented on the long-term efficacy of rifaximin therapy in patients with irritable bowel syndrome and diarrhoea. "

05/01/2009 - "Hepatic venous pressure gradient values decreased significantly after intestinal decontamination with rifaximin in patients with alcohol-related decompensated cirrhosis and this might have been achieved through significant reduction of plasma endotoxin levels."
02/01/2012 - "Rifaximin is effective for the management of HE in patients with cirrhosis, particularly in populations with MELD scores ≤20. "
01/01/2015 - "Adults with cirrhosis and history of overt HE episodes, currently in HE remission, received placebo during the RCT and crossed over to rifaximin 550 mg twice daily during the OLM study. "
07/01/2012 - "Intestinal decontamination with rifaximin improved systemic hemodynamics and renal function in patients with advanced cirrhosis."
10/01/2011 - "Patients with cirrhosis in remission from HE (Conn score = 0 or 1) and a documented history of recurrent HE episodes (≥2 within 6 months of screening) were randomised to rifaximin 550 mg twice daily (N = 101) or placebo (N = 118) for 6 months. "

10/01/2007 - "A larger trial would be required to determine if rifaximin is effective for the treatment of active pouchitis. "
01/01/2008 - "This historical cohort open-label study investigated the efficacy and tolerability of rifaximin in maintaining symptomatic and endoscopic remission in patients with antibiotic-dependent pouchitis. "
10/01/2007 - "The efficacy of the nonabsorbable antibiotic rifaximin in patients with active acute or chronic pouchitis is unknown. "
01/01/2008 - "Patients' response to rifaximin as a maintenance therapy appears to be favorable in this open-labeled trial of antibiotic-dependent pouchitis. "
10/01/2007 - "We performed a placebo-controlled pilot trial to evaluate the efficacy and safety of rifaximin in patients with active pouchitis. "